Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.
AUTHORS
Sutter
RW ,
Bahl
S ,
Deshpande
JM ,
Verma
H ,
Ahmad
M ,
Venugopal
P ,
Rao
JV ,
Agarkhedkar
S ,
Lalwani
SK ,
Kunwar
A ,
Sethi
R ,
Takane
M ,
Mohanty
L ,
Chatterjee
A ,
John
TJ ,
Jafari
H ,
Aylward
RB ,
. Lancet (London, England). 2015 9 17; ().
- PMID: 26388534 [PubMed].
ABSTRACT
Polio eradication needs a new routine immunisation schedule-three or four doses of bivalent type 1 and type 3 oral poliovirus vaccine (bOPV) and one dose of inactivated poliovirus vaccine (IPV), but no immunogenicity data are available for this schedule. We aimed to assess immunogenicity of this vaccine schedule.
Polio eradication needs a new routine immunisation schedule-three or four doses of bivalent type 1 and type 3 oral poliovirus vaccine (bOPV) and one dose of inactivated poliovirus vaccine (IPV), but no immunogenicity data are available for this schedule. We aimed to assess immunogenicity of this vaccine schedule.
Tags: Alumni Publications 2015